Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
-
- Jesse M. Tettero
- Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
-
- Sylvie Freeman
- Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, United Kingdom
-
- Veit Buecklein
- Department of Medicine III, University Hospital, LMU Munich, Germany
-
- Adriano Venditti
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
-
- Luca Maurillo
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
-
- Wolfgang Kern
- MLL Munich Leukemia Laboratory, Munich, Germany
-
- Roland B. Walter
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
-
- Brent L. Wood
- Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles, California, USA
-
- Christophe Roumier
- Laboratory of Hematology, CHU Lille, France
-
- Jan Philippé
- Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
-
- Barbara Denys
- Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
-
- Jeffrey L. Jorgensen
- Department of Hematopathology, UT MD Anderson Cancer Center, Houston, Texas, USA
-
- Marie C. Bene
- Hematology Biology, Nantes University Hospital, Nantes, France
-
- Francis Lacombe
- Flow Cytometry Platform, University Hospital, Bordeaux, France
-
- Adriana Plesa
- Laboratory of Hematology and Flow Cytometry, CHU Lyon-Sud Hospital, Hospices Civils de Lyon, France
-
- Monica L. Guzman
- Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, USA
-
- Agnieszka Wierzbowska
- Department of Hematology, Medical University of Lodz, Poland
-
- Anna Czyz
- Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
-
- Lok Lam Ngai
- Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
-
- Adrian Schwarzer
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
-
- Costa Bachas
- Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
-
- Jacqueline Cloos
- Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
-
- Marion Subklewe
- Department of Medicine III, University Hospital, LMU Munich, Germany
-
- Michaela Fuering-Buske
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
-
- Francesco Buccisano
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
抄録
<jats:p>Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.</jats:p>
収録刊行物
-
- HemaSphere
-
HemaSphere 6 (1), e676-, 2021-12-22
Wiley